UV Smart Receives First-Ever FDA Clearance for UV-C TEE Probe Disinfection System
Key Insights
Netherlands-based UV Smart Technologies (search) has received FDA 510(k) clearance for its D60 (search) system, marking the first UV-C high-level disinfection device approved for TEE probe sterilization.
The D60 (search) system reduces disinfection time from approximately two hours with chemical methods to just two minutes using UV-C light (search) technology.
This breakthrough enables healthcare facilities to treat more patients per day while eliminating chemical costs and reducing wear on expensive cardiology (search) equipment.
Netherlands-based MedTech company UV Smart Technologies (search) has achieved a significant regulatory milestone with FDA 510(k) clearance for its D60 (search) TEE probe disinfection system, becoming the first UV-C high-level disinfection device in the world to receive FDA approval for this specific application. The clearance opens the door for UV Smart to launch its groundbreaking technology in the United States healthcare market.
Revolutionary Speed in Medical Device Disinfection
The D60 (search) system represents a dramatic advancement in the disinfection of transesophageal echocardiography (TEE) probes, sensitive medical instruments used for heart examination (search) in cardiology (search). While current cleaning and disinfection protocols using harsh chemicals typically require approximately two hours, the D60 achieves high-level disinfection in just two minutes using UV-C light (search) technology.
"This clearance will help fulfill the need in U.S. healthcare for validated options that reduce manual workload, improve safety, and support more efficient clinical workflows," says co-founder Thijs Kea.
Operational and Economic Impact
The technology addresses multiple healthcare efficiency challenges simultaneously. By enabling faster disinfection cycles, the D60 (search) allows healthcare facilities to treat more patients per day, effectively scaling facility capacity. The system also eliminates ongoing chemical costs and reduces wear and tear on costly cardiology (search) equipment, supporting both operational efficiency and long-term cost control.
For healthcare providers, the D60 (search) represents a significant improvement in workflow efficiency while fortifying safety for healthcare workers through the elimination of harsh chemical exposure during the disinfection process.
Company Growth and Market Position
UV Smart Technologies (search), founded in 2017 by Daan Hoek and Thijs Kea, has rapidly expanded from an innovative concept between two friends into an international organization. The company now operates in 35 countries and has established itself as the market leader in its segment, with approximately thirty employees across the Netherlands, Germany, and the United Kingdom.
The company's portfolio includes the D25, D45, and D60 (search) systems, specifically designed for disinfection of cardiology (search), gynecology, TEE, and ENT equipment respectively. With support from investor Chris Oomen, founder of Optiver, UV Smart has demonstrated that Dutch innovation can make healthcare better and more affordable worldwide.
Strategic Market Expansion
The FDA clearance marks UV Smart's entry into the next phase of its international growth strategy. The United States represents a significant market opportunity for the company's chemical-free high-level disinfection technology, as healthcare systems increasingly seek validated solutions that improve operational efficiency while maintaining the highest safety standards.
UV Smart now supplies hospitals and clinics across 35 countries, and with the forthcoming expansion to the United States, the company is positioning itself for strong global growth in the medical device disinfection market.